Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06582784 · ClinicalTrials.gov registry record · NA

IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)

A NA study of Depression and Cancer, sponsored by Medical University of South Carolina.

Recruiting
Registry status
NA
Development phase
279
Enrollment target
1
Study location

NCT06582784: Recruiting NA study of Depression and Cancer, sponsored by Medical University of South Carolina.

NCT06582784 is a NA study of Depression and Cancer that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 279 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06582784, a NA study of Depression and Cancer, is actively recruiting participants, sponsored by Medical University of South Carolina.

RECRUITING
Registry status
NA
Development phase
279 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood. Participants will be randomly assigned to either download the mobile app, "Moodivate", or not. Approximately 2/3 of participants enrolled will receive the mobile app and the remaining 1/3 will not. All participants will complete electronic questionnaire measures throughout the study period. Questionnaires will assess symptoms of depression, as well as your experiences using Moodivate and participating in this trial. Participation in this study will take about 12 weeks, beginning today. Participation in this study may help in the treatment of future cancer survivors. The greatest risks of this study include frustration, worsening of emotional distress, data breach, and/or loss of confidentiality. Alternative treatments include contacting your primary care provider or your oncology care team to discuss other available treatments for depressed mood.

Primary Outcome

Change in the Patient Health Questionnaire (PHQ-9) score from baseline. The PHQ-9 scoring is 1-27 where 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, 15-19 is moderately severe depression, and 20-27 is severe depression.

Interventions

  • BEHAVIORAL Behavioral Activation Therapy App
  • BEHAVIORAL Treatment as Usual

Study Locations (1)

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 279 participants
Start Date 2024-10-28
Est. Completion 2029-08-01
Phase NA

What NCT06582784 shows while recruiting

NCT06582784 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, below the 786-participant average among 679 other Depression trials with a reported enrollment target (65% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which Behavioral Activation Therapy App is the first listed.

NCT06582784 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT06582784 about?

NCT06582784 is a clinical study titled "IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)". The purpose of this research study is to evaluate a mobile application (app) for depression treatment called "Moodivate" among cancer survivors. Moodivate was developed by our research team to assist with the treatment of depressed mood. Participants will be randomly assigned to either download the...

What is the current status of trial NCT06582784?

This trial is currently recruiting. It is a NA study. The enrollment target is 279 participants. The study started on 2024-10-28. Estimated completion is 2029-08-01.

What conditions does trial NCT06582784 study?

This clinical trial studies the following conditions: Depression, Cancer, Depressive Symptoms.

What interventions are being tested in trial NCT06582784?

The interventions under investigation include: Behavioral Activation Therapy App (BEHAVIORAL), Treatment as Usual (BEHAVIORAL).

Who is sponsoring clinical trial NCT06582784?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06582784 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06582784's enrollment target sits among peer trials

279 160th of 679 higher than 520 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04783857 · 279 participants · Phase 4

    Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children

  • NCT05407324 · 279 participants · Phase 2

    Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

  • NCT06299748 · 279 participants

    A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

  • NCT06876662 · 279 participants · Phase 4

    A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT06582784, the US trial registry maintained by the National Library of Medicine. NCT06582784 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.